Trefoil peptide TFF2 treatment reduces VCAM-1 expression and leukocyte recruitment in experimental intestinal inflammation.
There is evidence for a beneficial effect of trefoil peptides in animal models of gastric damage and intestinal inflammation, but the optimal treatment strategy and the mechanistic basis have not been explored thoroughly. It has been suggested that these proteins may modulate the inflammatory response. The aims of this study were to compare the protective and curative value of systemic and topical trefoil factor family (TFF)2 administration in dextran sulfate sodium-induced experimental colitis and to investigate the relationship between the therapeutic effects of TFF2 and modulation of leukocyte recruitment and expression of cell adhesion molecules. Clinical and morphologic severity of colitis was evaluated at the end of the study (Day 10). Leukocyte-endothelial cell interactions were determined in colonic venules by fluorescence intravital microscopy. The expression of cell adhesion molecules vascular cell adhesion molecule 1 (VCAM-1) and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) was measured by the dual radiolabeled monoclonal antibody technique. Pretreatment with TFF2 by subcutaneous or intracolonic (ic) route ameliorated the clinical course of colitis, and the luminal route had a significantly superior effect. This beneficial effect was correlated with significant reductions in endothelial VCAM-1 but not MAdCAM-1 expression and leukocyte adhesion to intestinal venules, which returned to levels similar to those of controls. In established colitis, ic TFF2 treatment did not modify the severity of colonic lesions. In conclusion, TFF2 is useful in the treatment of colitis, and topical administration is superior to the systemic route. Reduction in adhesion molecule expression and leukocyte recruitment into the inflamed intestine contributes to the beneficial effect of this treatment.
Soriano-Izquierdo
Antonio
A
Hospital Clínic, IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain. panes@medicina.ub.es
Gironella
Meritxell
M
Massaguer
Anna
A
May
Felicity E B
FE
Salas
Antonio
A
Sans
Miquel
M
Poulsom
Richard
R
Thim
Lars
L
Piqué
Josep M
JM
Panés
Julián
J
D000818:Animals; D015815:Cell Adhesion Molecules; D002450:Cell Communication / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D003092:Colitis / Q000188:drug therapy*; D003106:Colon / Q000098:blood supply / Q000473:pathology; D004333:Drug Administration Routes; D004353:Drug Evaluation, Preclinical; D004730:Endothelium, Vascular / Q000473:pathology; D007136:Immunoglobulins / Q000032:analysis / Q000187:drug effects; D007962:Leukocytes / Q000473:pathology; D051379:Mice; D008815:Mice, Inbred Strains; D009077:Mucins; D009088:Mucoproteins / Q000032:analysis / Q000187:drug effects; D009124:Muscle Proteins; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000071164:Trefoil Factor-2; D019010:Vascular Cell Adhesion Molecule-1 / Q000032:analysis / Q000187:drug effects*; D014699:Venules / Q000473:pathology
D015815:Cell Adhesion Molecules; D007136:Immunoglobulins; C489082:Madcam1 protein, mouse; D009077:Mucins; D009088:Mucoproteins; D009124:Muscle Proteins; D010455:Peptides; C481546:TFF2 protein, mouse; D000071164:Trefoil Factor-2; D019010:Vascular Cell Adhesion Molecule-1